{"id":"NCT00690430","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease","officialTitle":"A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2008-06-04","resultsPosted":"2013-07-30","lastUpdate":"2013-07-30"},"enrollment":186,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Symptomatic Refractory Resistant Carcinoid Disease"],"interventions":[{"type":"DRUG","name":"Pasireotide","otherNames":["SOM230"]},{"type":"DRUG","name":"Octreotide","otherNames":["Sadostatin LAR"]}],"arms":[{"label":"Pasireotide LAR","type":"ACTIVE_COMPARATOR"},{"label":"Octreotide LAR","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this randomized, multicenter, Phase III study was to compare the efficacy of paseriotide LAR and octreotide LAR in patients whose disease-related symptoms are inadequately controlled by currently available somatostatin analogues.","primaryOutcome":{"measure":"Percentage of Patients Who Achieved Clinical Symptom Improvement by Randomization Stratum and Treatment.","timeFrame":"Month 6","effectByArm":[{"arm":"Pasireotide LAR","deltaMin":13.5,"sd":null},{"arm":"Octreotide LAR","deltaMin":28.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":62,"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","France","Germany","Israel","Italy","Norway","Poland","Singapore","Spain","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.novartisclinicaltrials.com/etrials/searchTrial.do?trialID=679"]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":53},"commonTop":["Fatigue","Hyperglycaemia","Diarrhoea","Nausea","Oedema peripheral"]}}